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Abstract
Using a novel isotopic dilution gas chromatography-mass spectrometry method, the
plasma kinetics of 4-hydroxyandrostenedione (4-OHA) after a single i.m. injection of 250 or
500 mg of the drug have been studied in two groups of postmenopausal women affected
by advanced breast cancer. Although the mean values of CMax (the maximum concentra-
tion), t\m=1/2\and AUC (the area under the curve) for the 500 mg dose group were higher, the
differences were not statistically significant, possibly because of the high intersubject
variability.
In addition, the 4-OHA levels in the breast adipose tissue of the quadrant where the
tumor was located were measured in another group of women affected by breast cancer
who received a 250 mg dose of drug 2, 7 and 15 days before surgical intervention. The
tissue concentrations of 4-OHA were more than five times higher than the corresponding
plasma concentrations; in addition they correlated significantly with the circulating levels
of the drug and showed an exponential disappearance pattern.
Endocrine-Related Cancer (1996) 3 137-143
Introduction
4-Hydroxyandrostenedione (4-OHA) is a suicide
inhibitor of aromatase and is more potent than
aminoglutethimide in vitro. 4-OHA has been demon¬
strated to be useful for the treatment of
postmenopausal breast cancer (Miller 1990). The
administration schedule (one injection every 2
weeks) was based on the observation that suppres-
sion of plasma estrogens persists for 14 days. The
dose usually employed is 250 or 500 mg every 2
weeks. However, the incidence of side-effects with
pain and inflammation at the injection site was less
with the dose of 250 mg every 14 days, and this
schedule has been adopted for parenteral use
(Dowsett et al. 1989). A randomised trial in 40 post¬
menopausal women with breast cancer compared the
effect of the two doses (250 or 500 mg every 2
weeks) on plasma estradiol levels showing the same
degree of suppression (Dowsett et al. 1989).
However the clinical non-randomised studies
performed with the two schedules gave contradictory
results. In one clinical study (Dowsett et al. 1989)
there was no difference in the response rate between
the two dose levels, while in another study the objec¬
tive responses were 28% in the 250 mg group and
46% in the 500 mg group (Bajetta et al. 1994).
Recently, Bulun & Simpson (1994), using
competitive polymerase chain reaction following
reverse transcription, have demonstrated that the
highest expression of P450 aromatase in the stromal
cell compartment of adipose tissue is in the quadrant
where the tumor is located. Since we have recently
developed an isotopie dilution gas chromatography-
mass spectrometry (GC-MS) method for the determi¬
nation of 4-OHA in human plasma (Guarna et al.
1989, Danza et al. 1993) we have set up a similar
method for the measurement of this drug in the breast
adipose tissue ofpostmenopausal women affected by
breast cancer.
The present study was therefore organised to re-
investigate the plasma kinetics of 250 and 500 mg
doses of 4-OHA and, in addition, in another group of
patients treated with an i.m. injection of 250 mg
4-OHA at different intervals before surgery, to
measure the concentration of 4-OHA in adipose




For the plasma pharmacokinetic study, eight post¬
menopausal women with advanced breast cancer
received 250 or 500 mg 4-OHA. The mean(±S.D.)
age and body weight of the first group were 57(±6.4)
years and 63.5(±7.3) kg respectively, those of the
second group were 64.7(±11.5) years and
63(±8.7) kg respectively. Blood samples were
collected before and 4, 24, 48, 72, 96 192, 240 and
336 h after the injection of the drug. Immediately
after collection, the samples were centrifuged and
plasma was stored at -20 °C until analysis.
For the tissue pharmacokinetic study, eight
patients with breast cancer (see Table 2 for clinical
details), undergoing breast surgery, were treated with
an intramuscular injection of 250 mg 4-OHA at 2, 7
or 15 days before the operation. Tissue samples were
obtained at operation and immediately frozen at
-80 °C. Blood samples were taken before the injec¬
tion of the drug and just before the operation;
samples were centrifuged and plasma stored at
-20 °C until analysis.
This protocol has been approved by the ethical
committee of USL 10D, Florence, Italy, and written
informed consent was obtained from the patients.
Materials
4-OHA was a kind gift of Dr A Brodie (University of
Maryland, Baltimore, MD, USA). 7,7'-[2H]2-4-
Hydroxyandrostenedione (D2-4-OHA) was synthe-
sised in our laboratories as previously described
(Guama et al. 1989). The solvents used for the puri¬
fication procedure were analytical grade and were
purchased from J  Baker (Phillisburg, NJ, USA).
Extrelut 3 columns were purchased from Merck
(Darmstadt, Germany) and the Chromatographie
stationary phase Bio-beads SX3 was obtained from
Bio-Rad (Richmond, CA, USA). The HPLC instru¬
ment was a Perkin-Elmer LC series 3B. All GC-MS
analyses were performed using a Hewlett-Packard
(Palo Alto, CA, USA) GC-MS system with a 5890
series II gas Chromatograph equipped with a 5971A
mass spectrometry detector and a 7673A automatic
injector. The GC capillary column used was an HP1(12 m  0.2 mm  0.33 pm) (Hewlett-Packard).
Internal standard and stock and working
solutions
D2-4-OHA, synthesised as previously described
(Guama et al. 1989), was used as internal standard(IS). Working solutions of 4-OHA and D2-4-OHA in
ethanol were prepared by dilution of stock solutions(1 mg/ml in ethanol).
Analysis of plasma and adipose tissue
samples
Plasma samples were purified and analysed as previ¬
ously described (Danza et al. 1993). For the analysis
of adipose tissue samples a new method was estab¬
lished. The extraction of 4-OHA was performed
according to the following procedure: a tissue sample
of 0.5-1.0 g was minced with scissors and 20 ng IS
were added (20 µ 1 of 1 ng/pl solution). Minced
tissues were extracted with 3 x 5 ml methanol:
dichloromethane (90:10, v/v); the extracts were
concentrated to 1 ml under nitrogen, then 3 ml
cyclohexane:dichloromethane (85:15, v/v) were
added and the solutions were dried on short columns
of anhydrous Na2S04. The vials and the Na2S04
columns were then washed with 2  3 ml
cyclohexane:dichloromethane (85:15). The solutions
were evaporated to dryness under nitrogen; the
residues were redissolved with 0.5 ml
cyclohexane:dichloromethane (85:15) and the
resultant solutions were injected into a semiprep¬
arative low-pressure gel permeation column (Bio-
Beads SX3), gelified with cyclohexane:
dichloromethane (85:15), connected to the HPLC
instruments. The column was eluted at a flow rate of
1 ml/min and the fractions containing 4-OHA and
D2-4-OHA (23-33 min) were collected, evaporated





Figure 1 Plasma pharmacokinetic profiles of 4-OHA after a single i.m. injection of (a)
250 mg or (b) 500 mg of the drug.
Table 1 Mean values of plasma kinetic parameters for
the two doses of 4-OHA (250 and 500 mg)
Parameter 4-OHA (250 mg) 4-OHA (500 mg)
C^x (ng/ml) 10.78 17.9
tMax (h) 48 48
tK(h) 99.0 173.3
AUCq.336 (ng h/ml) 1279 2075.8
C336 (ng/ml) 1.011 3.05*
*P=0.006 compared with result for 250 mg 4-OHA.
room temperature with 25 pi bis-trimethylsilyl-
trifluoroacetamide to obtain the 4-O-trimethylsilyl
(4-O-TMS) derivative. The sample solutions were
evaporated to dryness under nitrogen, dissolved in
30 pi n-heptane and 3 pi were autoinjected into the
GC-MS instrument.
The mean analytical recovery of 4-OHA from
adipose tissue, calculated as previously described
(Guarna et al. 1995), was 63%.
The selectivity of the method was evaluated by
analysing blank samples and 4-OHA-free tissue
samples. The calibration curve was made with seven
points in the range 0-70 ng with 20 ng IS. Peak area
ratios of 4-OHA and IS were plotted versus 4-OHA
concentration and a good linearity was obtained
(r=0.997)
The precision and accuracy of the method were
determined by replicate interday analyses (n=3) of
tissue samples (0.5 g) at a 4-OHA concentration of
20 ng/g. Precision, evaluated by the coefficient of
variation, was 13%, and accuracy, calculated as mean
measured concentration versus nominal concentra¬
tion, was 92%.
The sensitivity limit of the instrument was eval¬
uated by injection of decreasing amounts of 4-OHA
and calculating the signal-noise ratio (S/N); 10 pg of
injected 4-OHA gave S/N=50. The sensitivity limit
of the assay was evaluated analysing tissue samples
(1 g) at decreasing concentrations of 4-OHA and
calculating S/N; samples at 500 pg/g gave S/N=30.4
when 3 pi of the 30 pi final volume were injected.
Analyses were performed using an HP1
(12 m  0.2 mm  0.33 pm) GC capillary column
with a 100% methylsilicone phase. The temperature
program was: 70 °C for 1 min, then an increase of
40 °C/min to 220 °C, 220 °C for 0.5 min, then an
increase of 3 °C/min to 300 °C. The transfer line
temperature was 280 °C. The carrier gas was helium
with an inlet pressure of 35 kPa. In these conditions,
the retention times of 4-OHA and D2-4-OHA were
14.14 min and 14.12 min respectively. Injections
were performed in the unsplit mode with a purge-off
time of 1 min and an injector temperature of 280 °C.
Selected ion monitoring analyses were made
acquiring the ions at 359.2 and 361.2 m/z corre¬
sponding to the M-15 fragment of the 4-O-TMS
derivatives of 4-OHA and D2-4-OHA respectively.
Plasma and tissue pharmacokinetic profiles
Plasma pharmacokinetic parameters for the two
doses of 4-OHA (250 and 500 mg) were calculated
as follows: CMax was the maximum concentration of
Table 2 Comparison between adipose breast tissue and plasma 4-OHA concentrations at different intervals
after a single 250 mg injection of the drug. The age, body weight, height and TNM staging system according to
the UICC classification are also reported for individual patients
Patient Age Body Height TNM Days Breast Plasma
(years) weight (cm) after adipose 4-OHA 4-OHA

























































Figure 2 Correlation between adipose breast tissue and plasma concentrations of
4-OHA after a single 250 mg injection (y=0.75+4.91 x, r=0.96).
the pharmacokinetic profile and tMax was the time at
which the maximum concentration was reached. The
ti/2 was calculated as t[/2=0.693/ATe/ where Kel is the
elimination constant. The AUC0_336 (area under the
curve) was calculated with the trapezoidal mie. C336
was the 4-OHA concentration at 336 h after the drug
injection. All the parameters for the two doses were
compared with Student's r-test.
For the tissue pharmacokinetic profile only the
elimination phase was valuable and the AUC was not
determined.
Results
The plasma kinetics of 4-OHA measured after the
injection of the two doses of 4-OHA are shown in
Fig. \a and b and the mean values of the relevant
parameters are reported in Table 1. In spite of the
large intersubject variability, the highest concentra¬
tion was obtained at 48 h with both doses. For that
reason, 2 days before surgical intervention was
chosen as the first point for the tissue study. Although
the CMax, t1/2 and AUC obtained with the 500 mg
dose were higher than those obtained with the
250 mg dose, the results were not significantly
different (P>0.05) when compared by Student's t-
test. Only the levels measured at 336 h (14 days)
were significantly higher (3.05 versus 1.011 ng/ml of
plasma, />=0.006) for the 500 mg dose. The tissue
concentrations of4-OHA were five times higher than
the corresponding plasma concentrations (Table 2);
they correlated significantly with circulating levels
of the drug (r=0.96) (Fig. 2) and showed an exponen¬
tial disappearance pattern (Fig. 3). The CMax in
breast adipose tissue and the apparent ti/2 were
respectively 94.4 ng/g and 57.8 h.
Discussion
The plasma kinetics of4-OHA after a single injection
of 250 or 500 mg of the drug have also been studied
by Dowsett et al. (1989) using an RIA. Their results
are in agreement with those of the present study
showing a maximal concentration of about 10 ng/ml
for the 250 mg dose and about 18 ng/ml for the
500 mg dose on the second day after injection. The
concentration of 4-OHA in breast adipose tissue









Figure 3 Exponential reduction of the concentration of 4-OHA in adipose breast tissue
after a single 250 mg injection of the drug.
been measured before. However, Reed et al. (1991)
measured 4-OHA levels in normal and tumor breast
tissue. They found that the concentration of drug in
breast tumor tissue was similar to that in plasma
while that in normal breast tissue was lower. They
found also a significant correlation between plasma
and tissue concentrations of the drug. In the present
study the circulating levels of 4-OHA still correlated
with the tissue levels but the concentration in adipose
tissue was five times higher than that in plasma. In
breast adipose tissue the concentration of 4-OHA
needed to reduce the aromatase activity to 50% has
been calculated to be 30 ng/g (Perei et al. 1981),
which is threefold lower than that which we meas¬
ured on the second day. On the basis of the apparent
tissue half-life we can calculate that 4-OHA levels
which are able to reduce the aromatase activity to
50% persist in breast adipose tissue for 6 days.
In conclusion, the ability to measure concentra¬
tions of 4-OHA in both plasma and breast adipose
tissue allows us to obtain new information regarding
the disposition of this potent and useful drug.
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